March 8, 2017

Tandem Diabetes Care Announces Filing of Registration Statement for Proposed Follow-on Public Offering of Common Stock

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed follow-on public offering of approximately $50 million of its common stock. All of the shares to be sold in the offering will be offered by Tandem. In addition, Tandem expects to grant to the underwriters a 30-day option to purchase up to approximately $7.5 million of additional common stock. The number of shares to be offered and the price for the proposed offering have not yet been determined. The offering will be subject to market conditions and other factors and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Piper Jaffray & Co. is acting as the sole book-running manager for the offering. Wedbush PacGrow is acting as a co-manager.

A registration statement relating to the securities has been filed with the Securities and Exchange Commission, but has not yet become effective. The securities may not be sold, nor may offers to buy the securities be accepted, prior to the time the registration statement becomes effective. The offering will be made only by means of a prospectus that forms a part of the registration statement. When available, copies of the prospectus relating to the offering may be obtained from: Piper Jaffray & Co. at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, or by calling 800-747-3924, or by emailing prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim X2™ Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements, and the t:slim G4™ Insulin Pump, the first continuous glucose monitoring-enabled pump with touchscreen simplicity. Tandem is based in San Diego, California.

t:flex and Tandem Diabetes Care are registered trademarks, and t:slim X2 and t:slim G4 are trademarks of Tandem Diabetes Care, Inc.

Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding the proposed follow-on public offering, including the anticipated amount to be raised in the offering. The Company's actual results, and the timing of events, could differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including market conditions at the time the Company conducts the proposed offering, the reaction of investors to the Company's recently announced financial condition, results of operations and liquidity position, and the Company's ability to satisfy closing conditions related to the proposed offering. In addition, our results may be impacted by the other risks identified in the Company's Registration Statement on Form S-1 relating to the offering, and other documents that the Company files with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Unless otherwise required by applicable law or the rules of the NASDAQ Stock Market, Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.

Tandem Diabetes Care, Inc.
Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com

Source: Tandem Diabetes Care®, Inc.

News Provided by Acquire Media


Close window | Back to top

Copyright 2017 Tandem Diabetes Care